Under the agreement, Cicel has committed to purchasing three Renaissance systems to pursue regulatory clearance from the State Food and Drug Administration in China and establish marketing activities there. The company expects regulatory clearance to take two years, and Cicel will have exclusive rights to market and distribute the system for the following three years.
More Articles on Orthopedic Devices:
TranS1 Reports 32% Drop in 4Q Revenue
Cleveland Clinic to Spin Off Orthopedic Preplanning Software
Titan Spine Expands to Europe With Subsidiary
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
